Despite a 1 percent drop in its third quarter profit, drug maker Astrazeneca Plc said Thursday that it was raising its annual earnings forecast after a favorable ruling in a United States patent case for its ulcer treatment Prilosec.
Astrazeneca reports lower quarterly profit favorable ruling in United States patent case.